What is ENDRA Life Sciences Inc (NDRA) stock price today?

ENDRA Life Sciences Inc (NDRA) currently trades at $4.87 per share. The stock has a market capitalization of $5.98M and a P/E ratio of —x.

Is NDRA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ENDRA Life Sciences Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is -35.22.

What is the NDRA stock price target for 2026?

WallStSmart's 12-month price target for ENDRA Life Sciences Inc is $4.29.

Is ENDRA Life Sciences Inc financially healthy?

ENDRA Life Sciences Inc's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of -35.22 places it in the distress.

NDRA

ENDRA Life Sciences Inc

NASDAQ: NDRA · HEALTHCARE · DIAGNOSTICS & RESEARCH

$4.87

+0.41% today

Updated 2026-04-30

Market cap

$5.98M

P/E ratio

—

P/S ratio

1,838.78x

EPS (TTM)

$-8.93

Dividend yield

—

52W range

$3 – $12

Volume

0.1M

Market cap

$5.98M

P/E ratio

—

P/S ratio

1,838.78x

EPS (TTM)

$-8.93

Dividend yield

—

52W range

$3 – $12

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

3.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-35.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$27.00

+454.41%

12-Month target

$4.29

-11.91%

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Altman Z -35.22 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-4.61M

- Debt/equity 3.07x — high leverage

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-13.18M	$-10.06M	$-11.51M	$-7.03M	$-3.17M
EPS	—	—	—	—	$-8.93
Free cash flow	$-12.97M	$-9.58M	$-7.42M	$-5.20M	$-4.61M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NDRA	$5.98M	22	4.3	3.0	5.0	3.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ENDRA Life Sciences Inc trades at $4.87. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -35.22, it sits in the distress.

Frequently asked questions

What is ENDRA Life Sciences Inc's stock price?

ENDRA Life Sciences Inc (NDRA) trades at $4.87.

Is ENDRA Life Sciences Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of ENDRA Life Sciences Inc (NDRA)?

The analyst target price is $27.00, representing +454.4% upside from the current price of $4.87.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

-35.22 — distress.

Company info

SectorHEALTHCARE

IndustryDIAGNOSTICS & RESEARCH

CountryUSA

ExchangeNASDAQ

CurrencyUSD

endrainc.com

Quick metrics

P/S ratio1,838.78x

ROE-291.60%

Beta-0.22

50D MA$4.24

200D MA$4.98

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NDRA vs LLY →NDRA vs JNJ →NDRA vs ABBV →Stock screener →